Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 147

1.

Reply.

Shah SC, Colombel JF, Sands BE, Narula N.

Clin Gastroenterol Hepatol. 2016 Apr 9. pii: S1542-3565(16)30062-3. doi: 10.1016/j.cgh.2016.04.002. [Epub ahead of print] No abstract available.

PMID:
27073132
2.

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Lennerz JK, van der Sloot KW, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park do Y, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, Iafrate AJ, Lauwers GY.

Int J Colorectal Dis. 2016 May;31(5):973-82. doi: 10.1007/s00384-016-2574-x. Epub 2016 Mar 30.

PMID:
27026089
3.

Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.

Shapiro JM, Zoega H, Shah SA, Bright RM, Mallette M, Moniz H, Grabert SA, Bancroft B, Merrick M, Flowers NT, Samad Z, Lidofsky S, LeLeiko NS, Sands BE.

Inflamm Bowel Dis. 2016 Feb 29. [Epub ahead of print]

PMID:
26926039
4.

The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG.

Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079. [Epub ahead of print]

5.

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Shah SC, Colombel JF, Sands BE, Narula N.

Clin Gastroenterol Hepatol. 2016 Jan 30. pii: S1542-3565(16)00107-5. doi: 10.1016/j.cgh.2016.01.015. [Epub ahead of print] Review.

PMID:
26829025
6.

Risk factors for radiation exposure in newly diagnosed IBD patients.

Grand DJ, Harris A, Shapiro J, Wu E, Giacalone J, Sands BE, Bright R, Moniz H, Mallette M, Leleiko N, Wallenstein S, Samad Z, Merrick M, Shah SA.

Abdom Radiol (NY). 2016 Jan 27. [Epub ahead of print]

PMID:
26814500
7.

Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.

Shapiro JM, Hagin SE, Shah SA, Bright R, Law M, Moniz H, Giacalone J, Jackvony T, Taleban S, Samad Z, Merrick M, Sands BE, LeLeiko NS.

Dig Dis Sci. 2016 Jan 2. [Epub ahead of print]

PMID:
26725063
8.

Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A.

J Crohns Colitis. 2016 Apr;10(4):418-28. doi: 10.1093/ecco-jcc/jjv224. Epub 2015 Dec 30.

PMID:
26721935
9.

Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.

Shah SC, Colombel JF, Sands BE, Narula N.

Aliment Pharmacol Ther. 2016 Feb;43(3):317-33. doi: 10.1111/apt.13475. Epub 2015 Nov 25. Review.

PMID:
26607562
10.

Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.

Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E.

Inflamm Bowel Dis. 2016 Mar;22(3):607-14. doi: 10.1097/MIB.0000000000000597.

PMID:
26595549
11.

Genetics, Genetic Testing, and Biomarkers of Digestive Diseases.

Carethers JM, Braun J, Sands BE.

Gastroenterology. 2015 Oct;149(5):1131-3. doi: 10.1053/j.gastro.2015.08.049. Epub 2015 Aug 29. Review. No abstract available.

PMID:
26327133
12.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF.

Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25. Review.

PMID:
26303131
13.

Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study.

Townsend P, Zhang Q, Shapiro J, Webb-Robertson BJ, Bramer L, Schepmoes AA, Weitz KK, Mallette M, Moniz H, Bright R, Merrick M, Shah SA, Sands BE, Leleiko N.

Inflamm Bowel Dis. 2015 Aug;21(8):1935-41. doi: 10.1097/MIB.0000000000000445.

PMID:
26199992
14.

Biomarkers of Inflammation in Inflammatory Bowel Disease.

Sands BE.

Gastroenterology. 2015 Oct;149(5):1275-1285.e2. doi: 10.1053/j.gastro.2015.07.003. Epub 2015 Jul 9. Review.

PMID:
26166315
15.

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ.

J Crohns Colitis. 2015 Aug;9(8):607-16. doi: 10.1093/ecco-jcc/jjv077. Epub 2015 May 8.

16.

Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors.

Tinsley A, Naymagon S, Mathers B, Kingsley M, Sands BE, Ullman TA.

Scand J Gastroenterol. 2015;50(9):1103-9. doi: 10.3109/00365521.2015.1020862. Epub 2015 Apr 11.

PMID:
25866237
17.

Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?

Shapiro JM, Cho JH, Sands BE, LeLeiko NS.

Clin Gastroenterol Hepatol. 2015 May;13(5):842-6. doi: 10.1016/j.cgh.2015.02.028. Epub 2015 Feb 25. Review.

PMID:
25725444
18.

The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution.

Marion JF, Sands BE.

Gastroenterology. 2015 Mar;148(3):462-7. doi: 10.1053/j.gastro.2015.01.029. No abstract available.

PMID:
25702851
19.

Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial.

Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, Colombel JF, Moore S, Sands BE; HealthPROMISE Consortium Group.

JMIR Res Protoc. 2015 Feb 18;4(1):e23. doi: 10.2196/resprot.4042.

20.

Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting.

Krishnarao A, de Leon L, Bright R, Moniz H, Law M, Leleiko N, Sands BE, Merrick M, Shapiro J, Wallenstein S, Giacalone J, Shah SA.

Inflamm Bowel Dis. 2015 Mar;21(3):564-9. doi: 10.1097/MIB.0000000000000309.

PMID:
25581825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk